East Rutherford, NJ – September 26, 2017 – Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it has completed the installation of new, large scale manufacturing capacity at its cGMP facility in Karlskoga, Sweden and has also undertaken a multi-year construction project to increase the site’s waste water processing capabilities.
The expansion of the site’s manufacturing capabilities included the installation of various multi-purpose reactors, ranging from 4m3 to 12m3 in size, in addition to a 9m³ hydrogenation reactor.
The construction of a new waste water treatment plant to support the expansion and improve existing biological processes, is being phased over a three-year period. The 30.5M SEK ($3.5M) investment will process over 4,000m3 of water each day and handle variations in the composition of effluent. The majority of the construction project will be completed in 2017, with additional upgrades in 2018 and 2019. When completed, the facility will reduce the emission of nitrogen, total organic compounds and suspended material, improving the site’s environmental footprint.
“Our Karlskoga site is a crucial part of the company’s global manufacturing network, and these investments, to not only to increase capacity, but also to the supporting infrastructure, will enable the site to work efficiently both now, and into the future,” commented Bjarne Sandberg, Managing Director, Cambrex Karlskoga. He added, “At Cambrex we are committed to investing in small molecule development and manufacturing capabilities, and ensuring our facilities are both flexible and efficient to respond to the evolving needs of our customers.”
The expansion at Cambrex’s Swedish site is part of an ongoing strategic campaign to increase manufacturing capacity across its global network, and follows the announcement of the construction of a $24M, 4,500ft² highly potent API manufacturing facility at the Charles City, Iowa site, which is due to open in 2019.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com
Contact: Alex Maw
Director, Marketing and Communications
Tel: +44 7803 443 155